Wall Street analysts forecast that Zosano Pharma Corporation (NASDAQ:ZSAN) will announce earnings per share of ($0.15) for the current quarter, according to Zacks. Zero analysts have provided estimates for Zosano Pharma Corporation’s earnings. Zosano Pharma Corporation posted earnings per share of ($0.52) in the same quarter last year, which would suggest a positive year-over-year growth rate of 71.2%. The firm is expected to announce its next earnings results on Wednesday, November 8th.
On average, analysts expect that Zosano Pharma Corporation will report full-year earnings of ($0.79) per share for the current financial year. For the next year, analysts anticipate that the business will report earnings of ($0.76) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Zosano Pharma Corporation.
Zosano Pharma Corporation (NASDAQ:ZSAN) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. During the same period last year, the company posted ($0.54) EPS.
Separately, ValuEngine lowered Zosano Pharma Corporation from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th.
TRADEMARK VIOLATION WARNING: This report was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/25/analysts-expect-zosano-pharma-corporation-zsan-to-announce-0-15-eps.html.
Institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp raised its position in Zosano Pharma Corporation by 591.4% in the second quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 67,774 shares during the last quarter. Granite Point Capital Management L.P. purchased a new stake in shares of Zosano Pharma Corporation during the first quarter valued at approximately $285,000. Victory Capital Management Inc. purchased a new stake in shares of Zosano Pharma Corporation during the first quarter valued at approximately $449,000. Nexthera Capital LP purchased a new stake in shares of Zosano Pharma Corporation during the first quarter valued at approximately $950,000. Finally, Perceptive Advisors LLC purchased a new stake in shares of Zosano Pharma Corporation during the first quarter valued at approximately $950,000. Hedge funds and other institutional investors own 23.91% of the company’s stock.
Shares of Zosano Pharma Corporation (NASDAQ:ZSAN) opened at 0.8373 on Friday. The company’s 50-day moving average is $1.13 and its 200 day moving average is $1.56. Zosano Pharma Corporation has a 12 month low of $0.45 and a 12 month high of $3.54. The stock’s market capitalization is $32.85 million.
Zosano Pharma Corporation Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Get a free copy of the Zacks research report on Zosano Pharma Corporation (ZSAN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
